Evaluation of oral Selenium Sulfide effect on treatment of Refractory Obsessive Compulsive Disorder in a Randomized Double Blind Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180212038699N1

Enrollment

Registered

2018-05-04

Start date

2018-01-30

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Included patients suffer from Obsessive Compulsive Disorder use Selenium Sulfide capsule 200 mcg (manufactoty: Century, made in USA) once a day for 6 weeks plus Flu

Eligibility

Sex/Gender

All

Age

18 Years to 62 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 62 years Minimum score of Yale brown questionnaire should be 21 Obtaining written informed consent before entering into the study use fluoxetine 20 mg once a day

Exclusion criteria

Exclusion criteria: Pregnancy Internal diseases (diabetic patients , hypertension & ...) Psychotic patients and mood disorders and neurology diseases Thinking about suicide Addiction to alcohol and narcotics IQ below 80

Design outcomes

Primary

Measure	Time frame
Obsession and compulsion score in Yale–Brown Obsessive Compulsive Scale (Y-BOCS). Timepoint: measurement yale brown questionnaire score in the began of first week and in the end of sixth week. Method of measurement: yale brown questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Sayah Bargard

Ahvaz University of Medical Sciences

sayahbargard@gmail.com+98 61 3333 3477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026